AMEERA-1: Phase 1-2 Study of Amcenestrant, An Oral Selective Estrogen Receptor Degrader, With Palbociclib in Postmenopausal Women With ER+ HER2- Metastatic Breast Cancer

home / investigator-perspectives / ameera-1-phase-1-2-study-of-amcenestrant-an-oral-selective-estrogen-receptor-degrader-with-palbo

Sarat Chandarlapaty, MD, discusses the treatment landscape of metastatic ER+/HER2- breast cancer, including observations made from the results of the AMEERA-1 trial and the use of amcenestrant as a therapy option.